Lv11
34 积分 2021-04-09 加入
有志者，事竟成！
MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
2小时前
已完结
Can a High-Dose of Furmonertinib Effectively Address Unmet Needs in EGFR-Mutated NSCLC with Leptomeningeal Metastases?
9天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC
3个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
3个月前
已完结
Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
5个月前
已完结
The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells
5个月前
已完结
EGFR status assessment using reflex testing targeted next-generation sequencing for resected non-squamous non-small cell lung cancer
6个月前
已完结
TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases
6个月前
已完结
Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer
6个月前
已完结
Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases
7个月前
已完结
皖公网安备34019202002308
